Search
Helium He-3
go.drugbank.com/drugs/DB12940InvestigationalHelium He-3 is under investigation in clinical trial NCT00846014 (Asthma Exacerbation and Helium-3 MRI).
Dezamizumab
go.drugbank.com/drugs/DB15153InvestigationalDezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
Fosravuconazole
go.drugbank.com/drugs/DB15204InvestigationalFosravuconazole is under investigation in clinical trial NCT03378661 (BENDITA BEnznidazole New Doses Improved Treatment and Associations).
Neodymium
go.drugbank.com/drugs/DB15318ExperimentalNeodymium is under investigation in clinical trial NCT03525522 (Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus).
Beludavimab
go.drugbank.com/drugs/DB18952InvestigationalBeludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).
Sanfetrinem cilexetil
go.drugbank.com/drugs/DB19135InvestigationalSanfetrinem cilexetil is under investigation in clinical trial NCT05388448 (EBA, Safety and Tolerability of Sanfetrinem Cilexetil).
Acemannan
go.drugbank.com/drugs/DB19224InvestigationalAcemannan is under investigation in clinical trial NCT03250923 (Celagace™ Orarinse Solution for Treatment of Candidiasis).
Plamotamab
go.drugbank.com/drugs/DB18944InvestigationalPlamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (
LNP-nCoVsaRNA Vaccine
go.drugbank.com/drugs/DB15799ExperimentalThe vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells.
Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnThe approved application holder removed Merital capsules from the market on January 23, 1986. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.